vimarsana.com

Latest Breaking News On - Leuven centre for cancer biology - Page 1 : vimarsana.com

Discovery of three new brain tumor subtypes could help to identify novel, effective therapies

New brain tumor subtypes discovery may help develop treatments

KU Leuven enters international licence agreement on cancer therapy

KU Leuven enters international licence agreement on cancer therapy These updates are republished press releases and communications from members of the Science|Business Network ​​​​​TEAD inhibition holds great promise as a therapeutic approach as the Hippo pathway is genetically altered in up to 10% of cancers.  In mesothelioma, an aggressive and untreatable cancer often caused by asbestos exposure, 60 to 70% of patients have mutations in the Hippo pathway leading to striking sensitivity to TEAD-inhibitors.  SpringWorks Expects to Nominate a Development Candidate and Commence IND-Enabling Studies in 2022 LEUVEN, Belgium, May 6, 2021 – KU Leuven, CD3 and VIB today announced that they have entered into an exclusive worldwide license agreement with SpringWorks Therapeutics, Inc. (Nasdaq: SWTX) for a portfolio of novel small molecule inhibitors of the Transcriptional Enhanced Associate Domain (TEAD) family of transcription factors, designed for the potential treatme

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.